Daily Respiratory Research Analysis
Analyzed 63 papers and selected 3 impactful papers.
Summary
Analyzed 63 papers and selected 3 impactful articles.
Selected Articles
1. Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.
Across 15 RCTs (n=3,642), dupilumab, tezepelumab, and stapokibart consistently achieved larger reductions in nasal polyp and congestion scores than several comparators. No indirect evidence showed superiority of stapokibart (20–24 weeks) or tezepelumab (48–56 weeks) over dupilumab. Safety profiles were comparable.
Impact: Provides comparative, trial-based evidence to inform biologic selection in severe CRSwNP where head-to-head trials are lacking.
Clinical Implications: Dupilumab remains a robust first-line biologic, with tezepelumab and stapokibart emerging as strong alternatives. Choice can be tailored to comorbid asthma or aspirin-exacerbated respiratory disease, with expectation of similar safety.
Key Findings
- Dupilumab, tezepelumab, and stapokibart produced greater reductions in nasal polyp and congestion scores than depemokimab, mepolizumab, benralizumab, and omalizumab at specified timepoints.
- No significant indirect superiority was observed for stapokibart (20–24 weeks) or tezepelumab (48–56 weeks) over dupilumab.
- Subgroup analyses suggested tezepelumab superiority vs depemokimab/mepolizumab in patients with concomitant asthma at 48–56 weeks; safety was comparable across agents.
Methodological Strengths
- Network meta-analysis integrating 15 randomized trials enables indirect comparisons across seven biologics.
- Assessment at two clinically relevant time windows (20–24 and 48–56 weeks) with multiple secondary endpoints and subgroup analyses.
Limitations
- Indirect comparisons; absence of head-to-head trials limits definitive hierarchy.
- Missing timepoint data for some agents (e.g., stapokibart at 48–56 weeks, tezepelumab at 20–24 weeks) and potential heterogeneity across trials.
Future Directions: Conduct head-to-head RCTs among top-performing biologics; validate subgroup-specific advantages (e.g., asthma, AERD) and evaluate long-term safety and steroid/surgery-sparing effects.
BACKGROUND: Biologic therapies improve outcomes in severe chronic rhinosinusitis with nasal polyps (CRSwNP), but their comparative efficacy remains uncertain. OBJECTIVE: To compare the efficacy and safety of seven biologic agents (dupilumab, omalizumab, mepolizumab, benralizumab, depemokimab, tezepelumab, and stapokibart) for the treatment of severe CRSwNP. METHODS: We systematically reviewed randomized trials in PubMed and EMBASE evaluating biologic agents for severe CRSwNP. Primary outcomes were changes in nasal-polyp score (NPS) and nasal congestion score (NCS) at 20-24 and 48-56 weeks. Secondary outcomes included changes in loss-of-smell, SNOT-22, UPSIT, Lund-Mackay scores, need for nasal-polyp surgery or systemic corticosteroids, and safety. We used mean differences (MDs) and odds ratios with 95% confidence intervals (CIs) for analysis. RESULTS: Fifteen randomized trials involving 3,642 patients were included. At 20-24 weeks, dupilumab and stapokibart produced greater reductions in NPS and NCS compared to depemokimab, omalizumab, and benralizumab, with no significant differences between dupilumab and stapokibart for NPS (MD
2. Identification and functional validation of lactylation-related hub genes in idiopathic pulmonary fibrosis based on multi-omics analysis.
Multi-omics mapping identified DDX3X, BCLAF1, and NCL as lactylation-linked hub genes upregulated in IPF and localized to distinct cell types. Elevated pan-lactylation was observed in IPF tissue and models, and knockdown of each hub gene reduced EMT and fibroblast activation, implicating lactylation in IPF pathogenesis and nominating new targets.
Impact: Reveals a previously underappreciated epigenetic PTM (lactylation) as a driver of IPF biology with cross-system validation, opening therapeutic avenues beyond current antifibrotics.
Clinical Implications: While preclinical, the data prioritize lactylation machinery and hub genes (DDX3X, BCLAF1, NCL) as candidate targets and support rational combination strategies with antifibrotics.
Key Findings
- Identified DDX3X, BCLAF1, and NCL as lactylation-related hub genes upregulated in IPF and localized to macrophages/neutrophils, ciliated epithelium, and fibroblasts/macrophages.
- Pan-lactylation levels were elevated in IPF tissues and TGF-β1-stimulated models; gene knockdown reduced EMT and fibroblast activation.
- Hub genes correlated with immune microenvironment remodeling; docking suggested favorable binding with pirfenidone and curcumin.
Methodological Strengths
- Integrated WGCNA, single-cell transcriptomics, and PPI network analysis with in vitro/in vivo functional knockdown.
- Immune infiltration analysis (CIBERSORT) and molecular docking to bridge mechanistic and translational relevance.
Limitations
- Discovery-phase with limited quantitative details on in vivo efficacy and absence of causal in-human validation.
- Molecular docking does not confirm binding/functional inhibition; clinical sample sizes and cohorts not fully enumerated.
Future Directions: Elucidate lactylation writers/erasers/readers in IPF, validate targets in patient-derived systems and animal models, and develop selective inhibitors for translational testing.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible interstitial lung disease (ILD) characterized by high mortality and poorly understood pathogenesis. Lactylation, a recently identified post-translational modification (PTM), is closely associated with inflammatory responses and tissue fibrosis in various diseases. However, the expression patterns and potential roles of lactylation, as well as the key regulatory genes involved, have not been fully elucidated in IPF. This study aimed to identify lactylation-related hub genes in IPF through bioinformatics analysis and preliminary functional validation, to explore their therapeutic potential, and to evaluate their binding affinity with clinical drugs, providing a theoretical basis for future research on lactylation mechanisms and targeted interventions in IPF. METHODS: Transcriptomic and single-cell sequencing datasets from lung tissues of IPF patients and healthy controls (HC) were obtained from the Gene Expression Omnibus (GEO) database. Weighted Gene Co-expression Network Analysis (WGCNA) was performed to identify IPF-related gene modules. Lactylation-associated hub genes were determined by integrating lactylation-related gene sets with protein-protein interaction (PPI) network analysis. Seurat software and UMAP clustering were employed to identify cell-specific localization of hub genes in lung tissues. Preliminary functional validations, including immunohistochemistry (IHC), Western blotting (WB) for pan-lactylation detection, and gene knockdown assays, were conducted in vitro and in vivo. The CIBERSORT algorithm was applied to analyze immune cell infiltration profiles in IPF tissues. Molecular docking analyses were performed to assess the binding affinity of clinical antifibrotic drugs (pirfenidone and curcumin) with proteins encoded by hub genes. RESULTS: DDX3X, BCLAF1, and NCL were identified as lactylation-related hub genes in IPF and were specifically expressed in macrophages/neutrophils, ciliated epithelial cells, and lung fibroblasts/macrophages, respectively. The level of pan-lactylation was significantly elevated in IPF lung tissues and TGF-β1-stimulated cellular models. These three hub genes were significantly upregulated in IPF tissues compared with HC, and individual knockdown of each gene significantly inhibited alveolar epithelial-mesenchymal transition (EMT) and human fetal lung fibroblast (HFL1) activation. In addition, these hub genes were closely associated with immune microenvironment remodeling in IPF. Pirfenidone and curcumin demonstrated favorable binding affinity with the proteins encoded by these genes. CONCLUSION: The lactylation-related hub genes DDX3X, BCLAF1, and NCL are specifically expressed in distinct cell types within IPF lung tissues, and their upregulation may promote IPF progression by mediating alveolar epithelial EMT, fibroblast activation, and profibrotic immune infiltration, highlighting their potential as therapeutic targets for IPF. Aberrant lactylation activation may contribute to IPF pathogenesis. Pirfenidone and curcumin show promising binding affinity with these hub gene-encoded proteins, providing a theoretical basis for further investigation into lactylation-targeted therapeutic strategies in IPF.
3. Preventive effectiveness of respiratory syncytial virus vaccination in older adults: a multi-institutional cohort study.
In a propensity-matched cohort of 359,742 adults ≥50 years, RSV vaccination reduced RSV infection by 35% and RSV-associated lower respiratory tract disease by 31%, with consistent benefit across demographic and comorbidity subgroups.
Impact: Delivers timely, large-scale real-world evidence supporting RSV vaccination programs for older adults, reinforcing policy and clinical uptake.
Clinical Implications: Supports offering RSV vaccination to adults ≥50, especially those with comorbidities, and informs health systems on expected population-level impact.
Key Findings
- After 1:1 propensity score matching, 179,871 vaccinated vs 179,871 unvaccinated adults ≥50 were analyzed.
- Vaccination reduced RSV infection risk (HR 0.65; 95% CI 0.58–0.73; incidence 0.17 vs 0.27/100 person-years).
- RSV-associated lower respiratory tract disease was reduced (HR 0.69; 95% CI 0.60–0.79), with consistent benefits across age, sex, and comorbidity subgroups.
Methodological Strengths
- Very large multi-institutional cohort with 1:1 propensity score matching to balance confounders.
- Time-to-event analysis using Cox models with subgroup consistency checks.
Limitations
- Observational design susceptible to residual confounding and misclassification.
- Vaccine brand, dosing timing, and durability analyses not reported in detail.
Future Directions: Assess durability, brand-specific effectiveness, and outcomes in the oldest old and immunocompromised; evaluate impact on hospitalization and mortality.
BACKGROUND: This multi-institutional study evaluated the real-world effectiveness of respiratory syncytial virus (RSV) vaccination in preventing RSV infections among adults aged 50 and older. METHODS: Using data from the TriNetX Research Network, we included individuals aged ≥ 50 years between January 1, 2023, and May 31, 2026. Patients were categorized into vaccinated and unvaccinated groups, defined as those receiving any RSV vaccine and any non-RSV vaccine, respectively. After 1:1 propensity score matching, we estimated hazard ratios (HR) for the composite outcome of RSV infection using Cox proportional-hazards models. RESULTS: The study included 179,871 patients in each group after matching. The vaccinated group had a lower risk of RSV infection compared to the unvaccinated group (incidence rate: 0.17 vs. 0.27 per 100 person-years, HR, 0.65; 95% CI, 0.58-0.73). Additionally, the vaccinated group showed lower risks of RSV-associated lower respiratory tract disease (incidence rate: 0.12 vs. 0.19 per 100 person-years, HR, 0.69; 95% CI, 0.60-0.79). Risk reductions were consistent across subgroups defined by age, sex, and comorbidity. CONCLUSIONS: This large real-world study demonstrates the substantial effectiveness of RSV vaccination in preventing infections among older adults, a high-risk population. CLINICAL TRIAL NUMBER: Not applicable.